Virbac announces the approval of its first pharmaceutical for Swine and Cattle in the U.S. and a collaboration with Pharmgate

12/07/2021

Westlake, TX / Wilmington, NC

Westlake, TX / Wilmington, NC - Virbac is proud to announce the launch of its first product in the U.S. food production animal market with the FDA approval of Tulissin® 25 (tulathromycin injection) injectable solution and Tulissin® 100 (tulathromycin injection) injectable solution for use in cattle and swine. The product will be available in two concentrations: 100 mg/mL and 25 mg/mL to properly cover the two segments. Tulissin 100 injectable solution will be available in 500, 250, 100 and 50 mL bottles and Tulissin 25 Injectable Solution in 250 and 100 mL bottles.

 

Virbac will market the cattle products with its own direct sales force; whereas for swine, Virbac announces that it has entered into an agreement with Pharmgate. Under this arrangement, Pharmgate, with a very robust sales and technical services division, will represent Virbac to swine veterinarians and producers across the U.S.

Virbac has a very strong presence in the large animal health segment in several regions, including Asia, Pacific, Europe and Latin America. This will be Virbac’s first foray into this segment for the U.S. market.

“We are excited to collaborate with a reputable animal health organization, such as Virbac, as they launch a range of products into the U.S. large animal market,” says Ed Seed, head of Global Sales & Marketing for Pharmgate. “Adding this initial product, Tulissin 25 and Tulissin 100, to our portfolio over the coming year will expand our offering in fulfilling our customers’ complete therapeutic product needs.”

“We see the market authorization of Tulissin 25 and Tulissin 100 as a major accomplishment and are excited about our introduction into the food producing animal market for the U.S. I am convinced that Pharmgate, with its broad portfolio of products and strong field team, key relationships and expertise, is a perfect fit for Virbac to successfully enter the swine segment,” says Francois Fournier, president & CEO, Virbac North America.

 

Important Swine Safety Information

Tulissin 25® injectable solution

  • Do not inject more than 4 mL per injection site
  • Pre-slaughter withdrawal 5 days
  • Effects on reproduction have not been determined
  • There may be trim loss at the injection site at slaughter
  • Do not use in animals known to be hypersensitive to the product
  • Not for use in use in humans, chickens or turkeys

Access Prescribing Information

Tulissin 100® injectable solution

  • Do not inject more than 2.5 mL per injection site
  • Pre-slaughter withdrawal 5 days
  • Effects on reproduction have not been determined
  • There may be trim loss at the injection site at slaughter
  • Do not use in animals known to be hypersensitive to the product
  • Not for use in use in humans, chickens or turkeys

Access Prescribing Information

Important Cattle Safety Information

Tulissin 25® injectable solution

  • Not for use in ruminating cattle.
  • Contraindicated in animals previously found to be hypersensitive to the drug.
  • Do not inject more than 4 mL per injection site. Tulissin® 25 Injectable Solution has a pre-slaughter withdrawal time of 5 days in swine and pre-slaughter withdrawal time of 22 days in calves.

Access Prescribing Information

Tulissin 100® injectable solution

  • Not for use in female dairy cattle 20 months of age or older.
  • Contraindicated in animals previously found to be hypersensitive to the drug.
  • Do not inject more than 10 mL per injection site.
  • Tulissin® 100 Injectable Solution has a pre-slaughter withdrawal time of 18 days in cattle and pre-slaughter withdrawal time of 5 days in swine.

Access Prescribing Information

 

Focusing on animal health, from the beginning

At Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables us to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.

Virbac Stats.jpg

Pharmgate Animal Health LLC is the joint venture between Pharmgate LLC, the majority-owned U.S. subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline feed grade, chlortetracycline hydrochloride, and other animal health compounds and ECO Animal Health, London U.K., a leader in the development, registration and marketing of pharmaceutical products for global animal health markets including Aivlosin®, as well as a range of branded generic animal health therapeutic products.